Cargando…
The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea
BACKGROUND: To reduce out‐of‐pocket costs, the Korean government expanded health insurance reimbursement in anti‐cancer drugs for cancer patients in 2013. Our objective was to examine the impact of the benefit coverage expansion policy on healthcare utilization and overall survival (OS) among patien...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267115/ https://www.ncbi.nlm.nih.gov/pubmed/34145980 http://dx.doi.org/10.1002/cam4.3979 |
_version_ | 1783720073440002048 |
---|---|
author | Cho, Do‐Yeon Park, Juhee Kim, Dong‐Sook |
author_facet | Cho, Do‐Yeon Park, Juhee Kim, Dong‐Sook |
author_sort | Cho, Do‐Yeon |
collection | PubMed |
description | BACKGROUND: To reduce out‐of‐pocket costs, the Korean government expanded health insurance reimbursement in anti‐cancer drugs for cancer patients in 2013. Our objective was to examine the impact of the benefit coverage expansion policy on healthcare utilization and overall survival (OS) among patients with six types of solid cancer after the policy of expanding health insurance coverage. METHODS: This study analyzed a before‐and‐after retrospective cohort of patients newly diagnosed with six types of solid cancer (stomach cancer, colorectal cancer, lung cancer, liver cancer, breast cancer, and prostate cancer) from January 1, 2009 to December 31, 2015 in Korea. The intervention was the expansion of reimbursement in 2013. Multivariate Cox proportional hazards regression was used to estimate the policy effect. RESULTS: In total, 142,579 before and 147,760 patients after the benefit expansion, and after matched by age, gender, and stage, 132,440 before and 132,440 patients after policy were included in the analysis. Almost total medical expenditure increased for five types of cancer increased. The expansion of health insurance reimbursement was associated with significantly lower overall mortality compared with pre‐policy mortality for all six cancer sites. CONCLUSION: The policy of expanding health insurance reimbursement might have been associated with a significant increase in survival among cancer patients by ensuring access to health care and medicine. Although the reimbursement expansion timing differs for each cancer, it is believed that eliminating delayed treatment might rather lead to reduce medical expenses and improve health outcomes. |
format | Online Article Text |
id | pubmed-8267115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82671152021-07-13 The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea Cho, Do‐Yeon Park, Juhee Kim, Dong‐Sook Cancer Med Cancer Prevention BACKGROUND: To reduce out‐of‐pocket costs, the Korean government expanded health insurance reimbursement in anti‐cancer drugs for cancer patients in 2013. Our objective was to examine the impact of the benefit coverage expansion policy on healthcare utilization and overall survival (OS) among patients with six types of solid cancer after the policy of expanding health insurance coverage. METHODS: This study analyzed a before‐and‐after retrospective cohort of patients newly diagnosed with six types of solid cancer (stomach cancer, colorectal cancer, lung cancer, liver cancer, breast cancer, and prostate cancer) from January 1, 2009 to December 31, 2015 in Korea. The intervention was the expansion of reimbursement in 2013. Multivariate Cox proportional hazards regression was used to estimate the policy effect. RESULTS: In total, 142,579 before and 147,760 patients after the benefit expansion, and after matched by age, gender, and stage, 132,440 before and 132,440 patients after policy were included in the analysis. Almost total medical expenditure increased for five types of cancer increased. The expansion of health insurance reimbursement was associated with significantly lower overall mortality compared with pre‐policy mortality for all six cancer sites. CONCLUSION: The policy of expanding health insurance reimbursement might have been associated with a significant increase in survival among cancer patients by ensuring access to health care and medicine. Although the reimbursement expansion timing differs for each cancer, it is believed that eliminating delayed treatment might rather lead to reduce medical expenses and improve health outcomes. John Wiley and Sons Inc. 2021-06-18 /pmc/articles/PMC8267115/ /pubmed/34145980 http://dx.doi.org/10.1002/cam4.3979 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Cho, Do‐Yeon Park, Juhee Kim, Dong‐Sook The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea |
title | The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea |
title_full | The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea |
title_fullStr | The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea |
title_full_unstemmed | The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea |
title_short | The impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in Korea |
title_sort | impact of expanding health insurance coverage for anti‐cancer drugs on cancer survival in korea |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267115/ https://www.ncbi.nlm.nih.gov/pubmed/34145980 http://dx.doi.org/10.1002/cam4.3979 |
work_keys_str_mv | AT chodoyeon theimpactofexpandinghealthinsurancecoverageforanticancerdrugsoncancersurvivalinkorea AT parkjuhee theimpactofexpandinghealthinsurancecoverageforanticancerdrugsoncancersurvivalinkorea AT kimdongsook theimpactofexpandinghealthinsurancecoverageforanticancerdrugsoncancersurvivalinkorea AT chodoyeon impactofexpandinghealthinsurancecoverageforanticancerdrugsoncancersurvivalinkorea AT parkjuhee impactofexpandinghealthinsurancecoverageforanticancerdrugsoncancersurvivalinkorea AT kimdongsook impactofexpandinghealthinsurancecoverageforanticancerdrugsoncancersurvivalinkorea |